Viridian Therapeutics Management

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President at Magenta Therapeutics, Inc. since Febr...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stephen Mahoney	CEO, President & Director	less than a year	no data	no data
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	no data	no data
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	no data	no data
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	no data	no data
Vahe Bedian	Co-Founder & Scientific Advisor	no data	no data	no data
Seth Harmon	Senior VP of Finance and Accounting	less than a year	no data	no data
Thomas Beetham	Chief Operating Officer	less than a year	no data	no data
Jennifer Tousignant	Chief Legal Officer	less than a year	no data	no data
John Jordan	Vice President of Investor Relations & Corporate Communications	no data	no data	no data
Anthony Casciano	Chief Commercial Officer	less than a year	no data	no data
Thomas Ciulla	Chief Medical Officer	1.3yrs	no data	0.0012% $ 12.2k
Shan Wu	Chief Business Officer	less than a year	no data	no data

0.5yrs

Average Tenure

55.5yo

Average Age

Experienced Management: VRDN's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Stephen Mahoney	CEO, President & Director	less than a year	no data	no data
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	no data	no data
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	no data	no data
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	no data	no data
Arlene Morris	Independent Director	6.3yrs	US$174.80k	0% $ 0
Victor Ambros	Scientific Advisory Board Member	no data	no data	no data
Stefanie Dimmeler	Scientific Advisory Board Member	no data	no data	no data
Jeffery Molkentin	Scientific Advisory Board Member	no data	no data	no data
Eva van Rooij	Scientific Advisory Board Member	no data	no data	no data
Tomas Kiselak	Independent Chairperson of Board	3.5yrs	US$192.30k	0% $ 0
Jennifer Moses	Independent Director	2.8yrs	US$168.30k	0% $ 0
Peter Harwin	Independent Director	3.5yrs	US$168.80k	0% $ 0

3.5yrs

Average Tenure

51yo

Average Age

Experienced Board: VRDN's board of directors are considered experienced (3.5 years average tenure).

Viridian Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

President recently bought US$101k worth of stock

Recent updates

New minor risk - Share price stability

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 15%, EPS upgraded

Price target decreased by 8.0% to US$40.07

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Price target decreased by 10% to US$41.36

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 18%

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

President recently bought US$101k worth of stock

Consensus revenue estimates fall by 35%

President recently bought US$160k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Price target increased by 9.1% to US$47.08

Chief Medical Officer exercised options and sold US$708k worth of stock

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Consensus revenue estimates increase by 162%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Viridian Therapeutics board compensation committee approves inducement grants

Consensus forecasts updated

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Price target increased to US$39.22

Viridian Therapeutics Q2 2022 Earnings Preview

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

Viridian Therapeutics gets a new COO

Co-Founder notifies of intention to sell stock

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

CEO, President & Director notifies of intention to sell stock

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$2.22 loss per share (vs US$1.82 loss in 2Q 2020)

Consensus forecasts updated

Independent Director Joseph Turner has left the company

Independent Chairman of the Board Jeffrey Hatfield has left the company

Viridian Therapeutics (VRDN) Investor Presentation - Slideshow